The study analyzed that the candidiasis therapeutics pipeline comprises approximately 22 drug candidates, of which two drug candidates are in Phase III stage of development, while five drug candidates are in Phase II stage, one drug candidate is in Phase I stage, 10 drug candidates are in Pre-Clinical stage and four drug candidates are in the Discovery stage. Candidiasis is a common type of fungal infection caused by fungus known as candida. Candida is found in various parts of human body including mouth, skin or belly and is non-infectious until it gets right environment to multiply and grow uncontrollably. This result in occurring of the infection, known as candidiasis.
Browse Report Description at: https://www.psmarketresearch.com/market-analysis/candidiasis-therapeutics-pipeline-analysis
Insights on pipeline segments
As per the findings of the research, around 27.0% drug candidates of candidiasis pipeline are being developed to be administered by oral route, 9.0% by topical route and 27.0% are to be administered by other routes, which includes intravenous, inhalation and intramuscular. Route of administration of around 37.0% drug candidates of candidiasis pipeline was not disclosed.
Ample Designations from the U.S. Food and Drug Administration (USFDA) to the market players manufacturing drugs for Candidiasis
Many companies are involved in the development of drugs for the candidiasis therapeutics pipeline, with their products in different phases. Seren Pharmaceuticals, Inc. and SCYNEXIS, Inc. have their drug candidates in the Phase III stage of development. ProFem GmbH, Matinas Biopharma Holdings, Inc. and Cidara Therapeutics, Inc. have their drug candidates in the Phase II stage of development. Sealife Pharma GmbH has two drug candidates in Pre-Clinical stage of development. Bionex Pharmaceuticals LLC has one drug candidate in Discovery stage of development.
The research also found that various companies received many designations from the U.S. Food and Drug Administration (USFDA) for the development of candidiasis therapeutics pipeline. In May 2016, USFDA granted the orphan drug designation to SCY-078 for the treatment of invasive candida infections, including candidemia. In January 2016, USFDA granted both fast track and qualified infectious disease product (QIDP) designations for the intravenous formulation of SCY-078 for the indications of invasive candidiasis (including candidemia) and invasive aspergillosis.
Some of the key players developing drugs for the treatment of candidiasis include Seren Pharmaceuticals, Inc., SCYNEXIS, Inc., Matinas Biopharma Holdings, Inc., Viamet Pharmaceuticals, Inc., NovaDigm Therapeutics, Inc., iCo Therapeutics, Inc., NovaBiotics Ltd., Bionex Pharmaceuticals LLC, Wellstat Therapeutics Corporation, Sealife Pharma GmbH and TGV-inhalonix.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-Free: +1-888-778-7886 (USA/Canada)